title: Letter to the editor in response to the commentary, "Concurrent administration of PTH and antiresorptives: Additive effects or DXA cosmetics.
authors.affiliation: Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Boston, MA, United States. Electronic address: bzleder@partners.org.
authors.forename: Benjamin Z
authors.initials: BZ
authors.lastname: Leder
authors.affiliation: Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Boston, MA, United States.
authors.forename: Joy N
authors.initials: JN
authors.lastname: Tsai
authors.affiliation: Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Boston, MA, United States.
authors.forename: Sherri-Anne
authors.initials: SA
authors.lastname: Burnett-Bowie
authors.affiliation: Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Boston, MA, United States; Department of Orthopedic Surgery, Beth Israel Deaconess Medical Center, Boston, MA, United States.
authors.forename: Mary L
authors.initials: ML
authors.lastname: Bouxsein
authors.affiliation: Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Boston, MA, United States.
authors.forename: Robert M
authors.initials: RM
authors.lastname: Neer
mesh_terms: D015519:Bone Density; D050071:Bone Density Conservation Agents; D003358:Cosmetics; D006801:Humans; D010024:Osteoporosis; D019379:Teriparatide
chemical_list: D050071:Bone Density Conservation Agents; D003358:Cosmetics; D019379:Teriparatide
keywords: Combination therapy; Denosumab; Osteoporosis; Teriparatide